Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients

DOI Web Site Web Site PubMed 被引用文献2件 参考文献10件 オープンアクセス
  • Mei Takanori
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
  • Noguchi Hiroshi
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
  • Suetsugu Kimitaka
    Department of Pharmacy, Kyushu University Hospital
  • Hisadome Yu
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
  • Kaku Keizo
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
  • Okabe Yasuhiro
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University
  • Masuda Satohiro
    Department of Pharmacy, International University of Health and Welfare Narita Hospital
  • Nakamura Masafumi
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University

この論文をさがす

説明

<p>Vonoprazan fumarate (vonoprazan) is a new kind of acid suppressant with potent acid inhibitory effects. Therefore, it has been administered to kidney transplant recipients for treatment or prophylaxis of steroid ulcers, refractory peptic ulcers, and gastroesophageal reflux disease. Because tacrolimus, which is a well-established immunosuppressant for kidney transplantation, and vonoprazan share the CYP3A4 system for metabolism, drug interactions are anticipated upon simultaneous administration. We retrospectively analyzed 52 kidney transplant recipients who were converted from rabeprazole, which has a small effect on the tacrolimus trough blood concentration (C0), to vonoprazan between August 2016 and July 2019. We compared the tacrolimus C0/tacrolimus dose (C0/D) before and after conversion and serum liver enzymes, serum total bilirubin, and the estimated glomerular filtration rate (eGFR). As a result, mean tacrolimus C0/D before and after conversion was 1.98 ± 1.02 and 2.19 ± 1.15 (ng/mL)/(mg/d), respectively, (p < 0.001). Additionally, mean aspartate transaminase (AST) before and after conversion was 18.6 ± 4.2 and 19.6 ± 5.2 IU/L, respectively, (p = 0.037). Mean alanine transaminase (ALT) before and after conversion was 15.8 ± 5.5 and 17.6 ± 7.1 IU/L, respectively, (p = 0.007). Mean eGFR before and after conversion was 50.6 ± 14.4 and 51.4 ± 14.7 mL/min/1.73 m2, respectively (p = 0.021). Mean AST, ALT, and eGFR were slightly but significantly elevated within normal ranges after conversion. In conclusion, our study suggests that the mean tacrolimus C0/D was elevated significantly by converting from rabeprazole to vonoprazan, but it had little clinical significance. Vonoprazan can be administered safely to kidney transplant recipients receiving tacrolimus.</p>

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (10)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ